All In Biotech

Drug Trial Radar · NCT07839338

A Study Comparing Oral Ketamine With Oral Midazolam for the Treatment of Major Depressive Episodes

A Randomized, Double-blind, Active Placebo-controlled, Multicenter Trial of Efficacy and Safety of Adjunctive Oral Ketamine vs Oral Midazolam for Major Depressive Episodes

Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 220 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

220

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Oct 2029

Study completion Oct 2029

Sponsor

Sponsor type
Government (non-federal)
Collaborators
Indian Council of Medical Research
First posted
Sep 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients with depression are acutely distressed, often suicidal, and unable to meet the demands of everyday life. If proven effective in a rigorously conducted multicenter randomized controlled trial (RCT), oral ketamine would provide an affordable and scalable, intervention suitable for integration into routine psychiatric services.This study will establish an indigenous, cost-effective therapeutic strategy that could improve accessibility, hasten therapeutic response, and inform treatment guidelines, if found to be safe and effective.

Conditions

  • Major Depressive Episode

Interventions

  • Oral ketamineDrug

    Nine sessions of oral ketamine

  • Oral midazolamDrug

    Nine sessions of oral midazolam

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hamilton Depression Rating Scale (HAM-D)Time frame: End of study week 3 (±2 days)

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • NIMHANS

    Bangalore, Karnataka, India

  • Kasturba Medical College

    Udupi, Karnataka, India

  • MGM Medical College, Mumbai

    Mumbai, Maharashtra, India

  • AIIMS, Bhubaneswar

    Bhubaneswar, Odisha, India

  • Jawaharlal Institute of Postgraduate Medical Education and Research

    Puducherry, Puducherry, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.